NCT05316389 (QUARLAMI) is a clinical trial of Breast reconstruction in Breast Cancer, sponsored by Institut Cancerologie de l'Ouest.

Who is sponsoring NCT05316389?

NCT05316389 is sponsored by Institut Cancerologie de l'Ouest.

What drugs are being tested in NCT05316389?

Interventions in NCT05316389: Breast reconstruction.

What condition does NCT05316389 study?

NCT05316389 studies Breast Cancer.

Is NCT05316389 still recruiting?

NCT05316389 is currently active, enrolled. Last updated 11 March 2026.

Last reviewed 2026-03-11 · How we verify

NCT05316389: QUARLAMI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retrospective and Prospective Evaluation of Scapulohumeral Comfort, Aesthetic Result and Quality of Life

Active, enrolled Last updated 11 March 2026

What this trial tests

trial testing Breast reconstruction in Breast Cancer in 190 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

21 February 2022

Primary endpoint
11 June 2026

21 February 2027

Quick facts

Lead sponsor	Institut Cancerologie de l'Ouest
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	190
Start date	21 February 2022
Primary completion	11 June 2026
Estimated completion	21 February 2027
Sites	1 location across France

Drugs / interventions tested

Breast reconstruction

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Institut Cancerologie de l'Ouest — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The dorsalis major flap is an interesting therapeutic option in breast reconstruction because of reliability and reproducibility. In recent years, the minimal flap technique has been developed, which consists of removing only a portion of the of the large dorsal muscle to reduce the painful and functional sequelae of this surgery. The objective of this prospective study is to evaluate the functional and aesthetic results in patients who have undergone who have undergone this procedure (prospective cohort) or who will undergo this procedure or prosthetic reconstruction (prospective cohort). The investigators also wish to evaluate the quality of life of patients after reconstruction with a minimal harvest dorsalis flap or a prosthesis or prosthesis in the prospective cohort.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Oncoplastic breast reconstruction using a muscle sparing latissimus dorsi flap: A retrospective analysis of esthetic results and scapula-humeral function.
De Freitas J, Reynard A, Guérin-Charbonnel C, Seegers V, et al · · 2026 · PMID 41624396 · DOI 10.1016/j.jpra.2025.12.007

Verify or expand the search:

Other trials of Breast reconstruction

Trials testing the same drug.

NCT05233891 — Validation of Scales in Reconstructive Breast Surgery · recruiting
NCT04343820 — Delayed Breast Reconstruction by Prepectoral Implant After Lipo-preparation (RM2prepec) · completed
NCT03963427 — Quality of Life, Aesthetic Result and Health Economy in Breast Reconstruction · NA · active not recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Institut Cancerologie de l'Ouest trials

Trials by the same sponsor.

NCT06978296 — HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymp · NA · not yet recruiting
NCT06967987 — Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2- · Phase 2 · withdrawn
NCT06756802 — Reproductive Health in Breast Cancer Survivor · active not recruiting
NCT07007325 — Prospective Feasibility Pilot Study Evaluating the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small · EARLY_PHASE1 · not yet recruiting
NCT06994702 — Impact of the MRI Restraint System on the Quality of the Synthetic Scan for Intracranial Radiotherapy Treatment · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05316389 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Cancerologie de l'Ouest
Last refreshed: 11 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05316389.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing